scholarly journals Response to sorafenib treatment in advanced metastatic thyroid cancer

2014 ◽  
Vol 58 (1) ◽  
pp. 37-41 ◽  
Author(s):  
Fabian Pitoia
Keyword(s):  
Heart Failure ◽  
Adverse Event ◽  
Thyroid Cancer ◽  
Partial Response ◽  
Progressive Disease ◽  
Tumor Regression ◽  
Sorafenib Treatment ◽  
Off Label ◽  
Unacceptable Toxicity ◽  
Metastatic Thyroid Cancer

Objective: To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma.Subjects and methods: Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months).Results: Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%.Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death.Conclusion: These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled.

scholarly journals Associations between plasma concentrations of lenvatinib and angiopoietin and clinical responses to lenvatinib therapy in Japanese patients with thyroid cancer

2021 ◽  
Author(s):  
Maho Kumagai ◽  
Mitsuji Nagahama ◽  
Yumiko Akamine ◽  
Tomoko Ozeki ◽  
Akifumi Suzuki ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Partial Response ◽  
Cancer Patients ◽  
Progressive Disease ◽  
Plasma Concentrations ◽  
Japanese Patients ◽  
Inhibitory Effect ◽  
Change Rate ◽  
Clinical Responses ◽  
Median Change

Abstract The purpose of this study was to investigate the relationships among plasma concentrations (C0) of lenvatinib, angiopoietin (Ang)-1 and Ang-2, and clinical responses to lenvatinib therapy in thyroid cancer patients. The median change rates of Ang-1 and Ang-2 at 1 month after treatment from baseline in all patients were − 15.3% and − 48.4%, respectively. However, the change of Ang-1 and Ang-2 at 1 month from baseline did not correlate with lenvatinib C0. In patients with partial response (PR) and stable disease to lenvatinib, Ang-2 at 1 month were significantly lower than Ang-2 at baseline (P < 0.001 and P < 0.05, respectively), but were not significantly lower in patients with progressive disease. The area under the ROC for PR prediction was 0.667, giving the best sensitivity (69.2%) and specificity (73.9%) at a threshold of the change rate of Ang-2 of -49.83%. In patients who continued treatment with lenvatinib for 1 year, Ang-2 at 1 month and 1 year were significantly lower than those at baseline (each P < 0.001). The change of Ang-2 at 1 month after treatment from baseline rather than simply the Ang-2 level at baseline may be important as a biomarker of the inhibitory effect of angiogenesis by lenvatinib.

Abstract #619 Primary Lung Adenocarcinoma in a Sea of Metastatic Thyroid Cancer

2019 ◽  
Vol 25 ◽  
pp. 319-320
Author(s):  
Lourdes Rodriguez ◽  
Mary Baker ◽  
Daniel W Karakla ◽  
David Lieb
Keyword(s):  
Thyroid Cancer ◽  
Lung Adenocarcinoma ◽  
Primary Lung Adenocarcinoma ◽  
Metastatic Thyroid Cancer

scholarly journals Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers

2021 ◽  
Vol 9 (4) ◽  
pp. e001752
Author(s):  
Rivka R Colen ◽  
Christian Rolfo ◽  
Murat Ak ◽  
Mira Ayoub ◽  
Sara Ahmed ◽  
...  
Keyword(s):  
Partial Response ◽  
Stable Disease ◽  
Progressive Disease ◽  
Tumor Response ◽  
Complete Response ◽  
Classification Model ◽  
P Value ◽  
Rare Cancer ◽  
Rare Cancers ◽  
Contrast Enhanced Ct

BackgroundWe present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers.MethodsThe study included 57 patients with advanced rare cancers who were enrolled in our phase II clinical trial of pembrolizumab. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST). Patients were categorized as 20 “controlled disease” (stable disease, partial response, or complete response) or 37 progressive disease). We used 3D-slicer to segment target lesions on standard-of-care, pretreatment contrast enhanced CT scans. We extracted 610 features (10 histogram-based features and 600 second-order texture features) from each volume of interest. Least absolute shrinkage and selection operator logistic regression was used to detect the most discriminatory features. Selected features were used to create a classification model, using XGBoost, for the prediction of tumor response to pembrolizumab. Leave-one-out cross-validation was performed to assess model performance.FindingsThe 10 most relevant radiomics features were selected; XGBoost-based classification successfully differentiated between controlled disease (complete response, partial response, stable disease) and progressive disease with high accuracy, sensitivity, and specificity in patients assessed by RECIST (94.7%, 97.3%, and 90%, respectively; p<0.001) and in patients assessed by irRECIST (94.7%, 93.9%, and 95.8%, respectively; p<0.001). Additionally, the common features of the RECIST and irRECIST groups also highly predicted pembrolizumab response with accuracy, sensitivity, specificity, and p value of 94.7%, 97%, 90%, p<0.001% and 96%, 96%, 95%, p<0.001, respectively.ConclusionOur radiomics-based signature identified imaging differences that predicted pembrolizumab response in patients with advanced rare cancer.InterpretationOur radiomics-based signature identified imaging differences that predicted pembrolizumab response in patients with advanced rare cancer.

scholarly journals 99mTc-Labeled-rhTSH Analogue (TR1401) for Imaging Poorly Differentiated Metastatic Thyroid Cancer

Thyroid ◽  
2014 ◽  
Vol 24 (8) ◽  
pp. 1297-1308 ◽  
Author(s):  
Filippo Galli ◽  
Isabella Manni ◽  
Giulia Piaggio ◽  
Lajos Balogh ◽  
Bruce D. Weintraub ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Poorly Differentiated ◽  
Metastatic Thyroid Cancer

Treatment of metastatic thyroid cancer

1980 ◽  
Vol 9 (2) ◽  
pp. 383-404 ◽  
Author(s):  
Robert D. Leeper ◽  
Katsutaro Shimaoka
Keyword(s):  
Thyroid Cancer ◽  
Metastatic Thyroid Cancer
Sign in / Sign up

Export Citation Format

Share Document